EyePoint (EYPT) Other Accumulated Expenses (2012 - 2026)
EyePoint (EYPT) posted Other Accumulated Expenses of $701000.0 for Q1 2026, down 67.24% sequentially from $2.1 million in Q4 2025, and down 64.33% YoY from $2.0 million in Q1 2025.
Analysis
EyePoint (EYPT) Other Accumulated Expenses (2012 - 2026) Analysis & Trends
EyePoint has reported Other Accumulated Expenses for 15 years, with the latest figure at $701000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 64.33% year-over-year to $701000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $701000.0 (down 64.33% YoY) and the FY2025 annual result came in at $2.1 million, up 48.61% from the prior year.
- Other Accumulated Expenses eased to $701000.0 in Q1 2026 per EYPT's latest filing, from $2.1 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $2.1 million in Q4 2025 and troughed at $183000.0 in Q3 2023.
- A 5-year average of $882529.4 and a median of $753000.0 in 2025 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses tumbled 74.73% in 2023, then surged 761.84% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $1.8 million in 2022, then tumbled by 63.25% to $646000.0 in 2023, then soared by 122.91% to $1.4 million in 2024, then surged by 48.61% to $2.1 million in 2025, then sank by 67.24% to $701000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $701000.0, $2.1 million, and $434000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.68 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | 2.14 Mn |
| Sep 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 1.97 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 646,000.00 |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 970,000.00 |
| Mar 31, 2023 | 884,000.00 |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 926,000.00 |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 1.41 Mn |